Dublin, Ireland, April 27, 2017 – ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2017.

Gross business wins in the first quarter were $580 million and cancellations in the quarter were $59 million, resulting in net business wins of $521 million, a net book to bill of 1.21.

– In the first quarter net revenue grew 7.8% year on year to $432 million from $400.5 million in the same quarter last year.

– Income from operations increased by 12.7% to $85.7 million, or 19.8% of revenue, compared to $76.0 million or 19.0% for the same quarter last year.

– Net income in the quarter increased by 13.4% to $71.4 million compared with $63.0 million in the same quarter last year.

– Earnings per share increased to $1.29 per share on a diluted basis, from $1.12 per share for the same quarter last year, an increase of 15.2%.

– Day’s sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 47 days at March 31, 2017, compared with 50 days at the end of December 31, 2016 and 47 days at the end of March 2016.

Read More

ICON Awarded Best CRO at World Vaccine Congress 2017

ICON recognised for continually setting standards of excellence in vaccine development

Dublin, Ireland, 12 April 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Best Clinical Research Organisation at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington this week.

Read More

Almac to Exclusively Share Global Expertise in EU Product Launch Workshop

Craigavon, N.I., 15 March 2017 – Almac Group, the global contract development and manufacturing organisation, is delighted to announce a free, one-day exclusive knowledge sharing workshop entitled ‘Considerations for EU Product Launch’ on Thursday 11 May 2017 at The Carlton Hotel Dublin.

This complimentary workshop will discuss key aspects regarding launching a product into Europe with a focus on niche and orphan drugs and will include:

• European regulatory framework
• The importance of the role of the Qualified Person (QP)
• Key considerations for packaging, selection and design
• Strategies for stock optimisation
• Managing a complex EU supply chain
• Considerations for a temperature sensitive product

Read More

Insights and Innovation Presented regarding a Range of Clinical Trial Supply Topics

Craigavon, N.I., 14 Mar 2017 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced that a number of its key clinical supply experts will deliver presentations at leading global conferences throughout March and April.

Heather Bogle, Supply Chain Solutions Manager will speak at this years’ Clinical Trial Supply Europe Conference being held in Barcelona, 15-16 Mar 2017. Her presentation, entitled “Regulatory Impact: Technology, Tools, and Insight to Mitigate Risk”, will take place at 4pm on day one of the conference where she will share the stage with a growing list of other industry experts from across the globe.

Read More